Ratings by Lucid Capital Markets (Dev Prasad)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/24/2026 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2025 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 12/3/2025 | Palatin Technologies | PTN | New Coverage | Buy (N/A) |
19.63 (23.98) |
22.16% | Details | |
| 11/5/2025 | Verrica Pharmaceuticals | VRCA | New Coverage | Buy (N/A) |
3.28 (5.31) |
61.89% | Details | |
| 9/15/2025 | aTyr Pharma | ATYR | Downgrade | Neutral (Buy) |
6.03 (0.82) |
-86.4% | Details | |
| 8/25/2025 | Cue Biopharma | CUE | New Coverage | Buy (N/A) |
0.83 (0.30) |
-63.86% | Details | |
| 6/17/2025 | Opus Genetics | IRD | New Coverage | Buy (N/A) |
0.94 (4.89) |
420.21% | Details | |
| 5/23/2025 | Edesa Biotech Inc. | EDSA | New Coverage | Buy (N/A) |
2.01 (6.52) |
224.38% | Details | |
| 3/18/2025 | Palvella Therapeutics | PVLA | New Coverage | Buy (N/A) |
27.50 (134.39) |
388.69% | Details | |
| 12/17/2024 | Avalo Therapeutics Inc. | AVTX | New Coverage | Buy (N/A) |
9.42 (17.31) |
83.76% | Details | |
| 12/17/2024 | iBio, Inc. | IBIO | New Coverage | Buy (N/A) |
2.35 (2.61) |
11.06% | Details | |
| 12/17/2024 | CalciMedica | CALC | New Coverage | Buy (N/A) |
2.81 (0.73) |
-74.02% | Details | |
| 11/19/2024 | Inflarx NV | IFRX | New Coverage | Buy (N/A) |
1.74 (0.97) |
-44.25% | Details | |
| 11/19/2024 | aTyr Pharma | ATYR | New Coverage | Buy (N/A) |
3.01 (6.03) |
100.33% | Details |
